Captopril potentiates the myocardial infarct size-limiting effect of ischemic preconditioning through bradykinin B2 receptor activation

Journal of the American College of Cardiology

Volumn 28, Issue 6, 1996, Pages 1616-1622

  Miki, Takayuki ^a   Miura, Tetsuji ^a,b   Ura, Nobuyuki ^a   Ogawa, Takashi ^a   Suzuki, Katsuo ^a   Shimamoto, Kazuaki ^a   Iimura, Osamu ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; CAPTOPRIL; ICATIBANT; KININ;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CAPTOPRIL; HEMODYNAMIC PROCESSES; ISCHEMIC PRECONDITIONING, MYOCARDIAL; KININS; MYOCARDIAL INFARCTION; RABBITS; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ;

EID: 0030588961     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00371-3     Document Type: Article

References (42)

1. 1. Miura T, Iimura O. Infarct size limitation by preconditioning: its phenomenological features and the key role of adenosine. Cardiovasc Res 1993;27: 36-42.
2. 2. Downey JM, Miura T. The role of adenosine in ischemic preconditioning. In: Hori M, Maruyama Y, Reneman RS, editors. Cardiovascular Adaptation and Failure, Tokyo: Springer-Verlag; 1994:147-66.
3. 3. Deutsch E, Berger M, Kussmaul WG, Hirshfeld JW, Herrmann HC, Laskey WK. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation 1990;82:2044-51.
4. 4. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. Lancet 1993;342:276-7.
5. 1 receptors in rabbit heart. Circulation 1991;84:350-6.
6. 6. Tsuchida A, Miura T, Miki T, Shimamoto K, Iimura O. Role of adenosine receptor activation in myocardial infarct size limitation by ischaemic preconditioning. Cardiovasc Res 1992;26:456-61.
7. 7. Miura T, Ogawa T, Iwamoto T, Shimamoto K, Iimura O. Dipyridamole potentiates the myocardial infarct size-limiting effect of ischemic preconditioning. Circulation 1992;86:979-85.
8. 8. Kimura E, Hashimoto K, Furukawa S, Hayakawa H. Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. Am Heart J 1973;85:635-47.
9. 9. Matsuki T, Shoji T, Yoshida S, et al. Sympathetically induced myocardial ischaemia causes the heart to release plasma kinin. Cardiovasc Res 1987;21: 428-32.
10. 10. Wall TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Exp Ther 1994;270:681-9.
11. 11. Wirth K. Hock FJ, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991;102:774-7.
12. 12. Linz W, Wiemer G, Gohlke, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
13. 13. Nachlas NM, Schnitka TK. Macroscopic identification of early myocardial infarction by alterations in dehydrogenase activity. Am J Pathol 1963;42: 379-405.
14. 14. Shimamoto K, Ando T, Tanaka S, Iimura O. The determination of kinin and glandular kallikrein in human biological fluids. Atemw-Lungenkrkh Jahrgang 1988;14 Suppl:S29-36.
15. 15. Ludbrook J. Repeated measures and multiple comparisons in cardiovascular research. Cardiovasc Res 1994;28:303-11.
16. 16. Ytrehus K, Liu Y, Tsuchida A, et al. Rat and rabbit heart infarction: effects of anesthesia, perfusate, risk zone, and method of infarct sizing. Am J Physiol 1994;267:H2383-90.
17. 17. Iimura O, Shimamoto K, Tanaka S, et al. The mechanism of the hypotensive effect of captopril (converting enzyme inhibitor) with special reference to the kallikrein-kinin and renin-angiotensin systems. Jpn J Med 1986;25:34-9.
18. 18. Iimura O, Shimamoto K. Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension. J Cardiovasc Pharmacol 1989;13 Suppl 3:S63-6.
19. 19. Baumgarten CR, Linz W, Kunkel G, Scholkens BA, Wiemer G. Ramiprilat increases bradykinin outflow from isolated hearts of rat. Br J Pharmacol 1993;108:293-5.
20. 20. Wiemer G, Scholkens BA, Linz W. Endothelial protection by converting enzyme inhibitors. Cardiovasc Res 1994;28:166-72.
21. 21. Miki T, Miura T, Shimamoto K, Urabe K, Sakamoto J, Iimura O. Do angiotensin converting enzyme inhibitors limit myocardial infarct size? Clin Exp Pharmacol Physiol 1993;20:429-34.
22. 22. Liang C, Gavras H, Black J, Sherman LG, Hood WB, Renin-angiotensin system inhibition in acute myocardial infarction in dogs: effect on systemic hemodynamics, myocardial blood flow, segmental myocardial function and infarct size. Circulation 1982;66:1249-55.
23. 23. Daniell HB, Carson RR, Ballard KD, Thomas GR, Privitera PJ. Effects of captopril on limiting infarct size in conscious dogs. J Cardiovasc Pharmacol 1984;6:1043-7.
24. 24. Richard V, Ghaleh B, Berdeaux A, Giudicelli JF. Comparison of the effects of EXP3174, an angiotensin II antagonist and enalaprilat on myocardial infarct size in anaesthetized dogs. Br J Pharmacol 1993;110:969-74.
25. 25. Ertl G, Kloner RA, Alexander RW, Braunwald E. Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 1982;65:40-8.
26. 26. Lefer AM, Peck PC. Cardioprotective effects of enalapril in acute myocardial ischemia. Pharmacology 1984;29:61-9.
27. 27. Hock CE, Ribeiro LGT, Lefer AM. Preservation of ischemic myocardium by a new converting enzyme inhibitor, enalaprilic acid, in acute myocardial infarction. Am Heart J 1985;109:222-8.
28. 28. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist Hoe 140. J Cardiovasc Pharmacol 1993;21:996-1003.
29. 29. Itoya M, Miura T, Sakamoto J, Urabe K, Iimura O. Nucleoside transport inhibitors enhance the infarct size-limiting effect of ischemic preconditioning. J Cardiovasc Pharmacol 1994;24:846-52.
30. 30. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev 1992;44:1-80.
31. 31. Liu GS, Stanley AWH, Downey JM. Cyclooxygenase products are not involved in the protection against myocardial infarction afforded by preconditioning in rabbit. Am J Cardiovasc Pathol 1992;4:157-64.
32. 32. Goto M, Liu Y, Yang X-M, Ardell JL, Cohen MV, Downey JM. Role of bradykinin in protection of ischemic preconditioning in rabbit hearts. Circ Res 1995;77:611-21.
33. 33. Woolfson RG, Patel VC, Neild GH, Yellon DM. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation 1995;91:1545-51.
34. 34. Ytrehus K, Liu Y, Downey JM. Preconditioning protects ischemic rabbit heart by protein kinase C activation. Am J Physiol 1994;266:H1145-52.
35. 35. Liu Y, Cohen MV, Downey JM. Chelerythrine, a highly selective protein kinase C inhibitor, blocks anti-infarct effect of ischemic preconditioning in rabbit hearts [abstract]. Circulation 1994;90 Suppl 1:1-207.
36. 2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ Res 1995;76:773-80.
37. 2 receptors. Br J Pharmacol 1994;113:1167-72.
38. 38. Vegh A, Szekeres L, Parratt JR. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia induced arrhythmias in anaesthetized dogs. Br J Pharmacol 1991;104:294-5.
39. 39. Vegh A, Szekeres L, Parratt JR. Preconditioning of the ischaemic myocardium; involvement of the L-arginine nitric oxide pathway. Br J Pharmacol 1992;107:648-52.
40. 40. Black SC, Fagbemi SO, Chi L, Friedrichs GS, Lucchesi BR. Phorbol ester-induced ventricular fibrillation in the Langendorff-perfused rabbit heart: antagonism by staurosporine and glibenclamide. J Mol Cell Cardiol 1993;25:1427-38.
41. 41 Bruton J, Goto M, Downey JM. Endogenous angiotensin II contributes to ischemic preconditioning [abstract]. J Mol Cell Cardiol 1995;27:A43.
42. 42. Liu Y, Tsuchida A, Cohen MV, Downey JM. Pretreatment with angiotensin II activates protein kinase C and limits myocardial infarction in isolated rabbit hearts. J Mol Cell Cardiol 1995;27:883-92.